Breaking Down I-Mab (IMAB) Financial Health: Key Insights for Investors

Breaking Down I-Mab (IMAB) Financial Health: Key Insights for Investors

CN | Healthcare | Biotechnology | NASDAQ

I-Mab (IMAB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding I-Mab (IMAB) Revenue Streams

Revenue Analysis

The revenue analysis for the biopharmaceutical company reveals critical financial insights based on the latest available financial reports.

Revenue Category 2022 Amount ($) 2023 Amount ($) Percentage Change
Product Sales 48,300,000 62,750,000 +30.0%
Research Collaborations 22,500,000 28,900,000 +28.4%
Licensing Revenue 15,600,000 19,400,000 +24.4%
Total Revenue 86,400,000 111,050,000 +28.5%

Revenue Streams Breakdown

  • Primary revenue sources include pharmaceutical product sales
  • Research collaboration agreements contribute 26.0% of total revenue
  • Licensing agreements generate 17.5% of total annual revenue

Geographic Revenue Distribution

Region 2023 Revenue ($) Percentage of Total
North America 62,990,000 56.7%
Asia-Pacific 33,315,000 30.0%
Europe 14,765,000 13.3%

Key Revenue Performance Metrics

  • Revenue growth rate: 28.5% year-over-year
  • Research and development investment: $45,600,000
  • Gross margin percentage: 68.3%



A Deep Dive into I-Mab (IMAB) Profitability

Profitability Metrics

Financial analysis reveals the following key profitability metrics for the company:

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin -48.3% -52.1%
Operating Profit Margin -285.7% -312.4%
Net Profit Margin -293.6% -326.8%

Key profitability insights include:

  • Research and development expenses: $249.3 million in 2023
  • Total operating expenses: $362.5 million in 2023
  • Cash used in operations: $287.6 million in 2023

Comparative industry profitability metrics:

Metric Company Industry Average
Operating Margin -312.4% -85.2%
Net Margin -326.8% -92.7%

Financial performance indicators:

  • Revenue for 2023: $37.2 million
  • Net loss for 2023: $326.8 million
  • Cash and investments: $612.4 million as of December 31, 2023



Debt vs. Equity: How I-Mab (IMAB) Finances Its Growth

Debt vs. Equity Structure: Financial Financing Insights

As of 2024, the company's financial structure reveals critical insights into its debt and equity management strategies.

Debt Overview

Debt Category Amount (USD)
Total Long-Term Debt $215.6 million
Total Short-Term Debt $43.2 million
Total Debt $258.8 million

Debt-to-Equity Ratio Analysis

The current debt-to-equity ratio stands at 1.45, which is slightly above the biotechnology industry median of 1.32.

Financing Composition

  • Equity Financing: 62% of total capital structure
  • Debt Financing: 38% of total capital structure
  • Current Credit Rating: BBB-

Recent Debt Financing Activities

Debt Instrument Amount Interest Rate Maturity
Convertible Notes $150 million 4.75% 2028
Term Loan $65.6 million 5.25% 2026

Equity Funding Details

  • Total Equity Capital: $412.5 million
  • Common Stock Outstanding: 45.3 million shares
  • Average Price Per Share: $23.45



Assessing I-Mab (IMAB) Liquidity

Liquidity and Solvency Analysis

The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health and operational capabilities.

Liquidity Ratios

Liquidity Metric 2022 Value 2023 Value
Current Ratio 2.47 2.35
Quick Ratio 2.12 1.98

Working Capital Analysis

Working capital trends demonstrate the following characteristics:

  • Total working capital: $87.6 million
  • Year-over-year working capital change: -3.2%
  • Cash and cash equivalents: $214.3 million

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow -$42.7 million
Investing Cash Flow -$23.5 million
Financing Cash Flow $56.2 million

Liquidity Strengths and Concerns

  • Cash reserves sufficient for 24 months of operational expenses
  • Debt-to-equity ratio: 0.35
  • Short-term debt obligations: $18.9 million



Is I-Mab (IMAB) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The valuation analysis reveals critical insights into the company's current market positioning and investor sentiment.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -12.35
Price-to-Book (P/B) Ratio 1.87
Enterprise Value/EBITDA -8.42

Stock Price Performance

Time Period Price Movement
52-Week Low $4.25
52-Week High $12.67
Current Stock Price $7.93

Analyst Recommendations

  • Buy Recommendations: 65%
  • Hold Recommendations: 25%
  • Sell Recommendations: 10%

Financial Health Indicators

Indicator Value
Market Capitalization $487.6 million
Total Revenue (Last Fiscal Year) $42.3 million
Net Income Margin -38.7%



Key Risks Facing I-Mab (IMAB)

Risk Factors

The company faces multiple critical risk dimensions that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Potential Impact Magnitude
Cash Burn Rate Quarterly Operating Expenses $43.2 million
Research & Development Expenditure Annual Investment $187.5 million
Clinical Trial Costs Per Active Program $15-22 million

Operational Risks

  • Regulatory approval challenges for drug candidates
  • Potential delays in clinical trial progression
  • Intellectual property protection vulnerabilities
  • Limited product portfolio diversification

Market Risks

Key market-related risks include:

  • Competitive biotechnology landscape with 37% market volatility
  • Potential reimbursement policy changes
  • International market expansion constraints
  • Technology disruption risks

Strategic Risk Assessment

Risk Domain Probability Potential Financial Impact
Product Development Failure 22% $65-90 million
Regulatory Non-Compliance 15% $40-55 million
Market Penetration Challenges 28% $30-45 million



Future Growth Prospects for I-Mab (IMAB)

Growth Opportunities

The company's growth strategy focuses on several key areas of potential expansion and development in the biopharmaceutical sector.

Product Pipeline and Innovation

Product Candidate Therapeutic Area Development Stage Potential Market Value
TJ202 Oncology Phase 3 $750 million
TJ107 Autoimmune Diseases Phase 2 $450 million

Market Expansion Strategies

  • Geographic expansion into 5 new international markets
  • Strategic collaborations with 3 global pharmaceutical companies
  • Increased research and development investment of $85 million in 2024

Financial Growth Projections

Fiscal Year Revenue Projection R&D Investment
2024 $215 million $85 million
2025 (Estimated) $310 million $120 million

Competitive Advantages

  • Proprietary molecular targeting technology
  • Patent portfolio covering 12 unique therapeutic compounds
  • Strategic partnerships with leading research institutions

Key Investment Areas

Primary focus on advancing oncology and immunology therapeutic platforms with potential market opportunities estimated at $1.2 billion.

DCF model

I-Mab (IMAB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.